tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amplia Therapeutics Updates Director’s Interest Notice

Story Highlights
Amplia Therapeutics Updates Director’s Interest Notice

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Amplia Therapeutics ( (AU:ATX) ).

Amplia Therapeutics Limited has announced a change in the director’s interest notice for Dr. Christopher Burns, reflecting updates in his securities holdings. This announcement, authorized by the company’s secretary, highlights the ongoing management and regulatory compliance within the company, potentially impacting investor perceptions and stakeholder confidence.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

More about Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic cancer and chronic diseases like idiopathic pulmonary fibrosis (IPF).

YTD Price Performance: 74.16%

Average Trading Volume: 7,216,964

Technical Sentiment Signal: Hold

Current Market Cap: A$79.53M

For an in-depth examination of ATX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1